Differences in the adverse effects of azathioprine between inflammatory bowel disease and autoimmune hepatitis in Korean patients.

Korean J Gastroenterol 2014 Dec;64(6):348-55

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Background/aims: Azathioprine (AZA) has been widely used in the therapy of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). However, studies evaluating the adverse effects of AZA in these two diseases are lacking. The aim of this study was to compare the adverse effects of AZA in Korean IBD and AIH patients.

Methods: Patients with IBD or AIH who were treated with AZA at Keimyung University Dongsan Medical Center (Daegu, Korea) between January 2002 and March 2011 were enrolled. Their medical records were reviewed retrospectively in terms of clinical characteristics and adverse effects of AZA.

Results: A total of 139 IBD patients and 55 AIH patients were finally enrolled. Thirty IBD patients (21.6%) and eight AIH patients (14.5%) experienced adverse effects of AZA. In particular, the prevalence of leukopenia was significantly higher in the IBD group than in the AIH group (p=0.026). T474C mutation was observed in three of 10 patients who were assessed for thiopurine methyltransferase (TPMT) genotype.

Conclusions: IBD patients are at increased risk for the adverse effects of AZA compared with AIH patients, of which leukopenia was the most commonly observed. Therefore, IBD patients receiving AZA therapy should be carefully monitored.

Download full-text PDF

Source
http://dx.doi.org/10.4166/kjg.2014.64.6.348DOI Listing
December 2014
24 Reads

Publication Analysis

Top Keywords

adverse effects
24
effects aza
16
ibd patients
16
aih patients
12
patients
10
aza therapy
8
ibd aih
8
autoimmune hepatitis
8
bowel disease
8
ibd
8
inflammatory bowel
8
aza
7
aih
7
effects
6
adverse
5
patients finally
4
patients 216%
4
145% experienced
4
experienced adverse
4
aza prevalence
4

Similar Publications